IL-6/STAT3 is an important therapeutic target for HCC [15], and targeted drugs for HCC patients with elevated pre-RT IL-6 who experience relapse may become a promising treatment strategy. The gene discussed is STAT3; the disease is hepatocellular carcinoma.